[1] ASRANI S K, DEVARBHAVI H, EATON J, et al. Burden of liver diseases in the world[J]. J Hepatol, 2019, 70(1):151-171.
[2] SEKI E, SCHWABE R F. Hepatic inflammation and fibrosis:functional links and key pathways[J]. Hepatology, 2015, 61(3):1066-1079.
[3] AYD\U0131N M M, AKÇAL\U0131 K C. Liver fibrosis[J]. Turk J Gastroenterol, 2018, 29(1):14-21.
[4] KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021,18(3):151-166.
[5] SEKI E, SCHWABE R F. Hepatic inflammation and fibrosis:functional links and key pathways[J]. Hepatology, 2015, 61(3):1066-1079.
[6] CAMPANA L, IREDALE J P. Regression of liver fibrosis[J]. Semin Liver Dis, 2017, 37(1):1-10.
[7] ELLIS E L, MANN D A. Clinical evidence for the regression of liver fibrosis[J]. J Hepatol, 2012, 56(5):1171-1180.
[8] ISSA R, ZHOU X Y, CONSTANDINOU C M, et al. Spontaneous recovery from micronodular cirrhosis:evidence for incomplete resolution associated with matrix cross-linking[J]. Gastroenterology, 2004, 126(7):1795-1808.
[9] POYNARD T, MCHUTCHISON J, MANNS M, et al. Impact of pegylated interferon Alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C[J]. Gastroenterology, 2002, 122(5):1303-1313.
[10] HIGASHI T, FRIEDMAN S L, HOSHIDA Y. Hepatic stellate cells as key target in liver fibrosis[J]. Adv Drug Deliv Rev, 2017, 121:27-42.
[11] MARTÍ-RODRIGO A, ALEGRE F, MORAGREGAÁB, et al.Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells[J]. Gut, 2020, 69(5):920-932.
[12] LUEDDE T, SCHWABE R F. NF-κB in the liver:linking injury,fibrosis and hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(2):108-118.
[13] BORKHAM-KAMPHORST E, SCHAFFRATH C, VAN DE LEUR E,et al. The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-β signaling[J]. Biochim Biophys Acta, 2014, 1843(5):902-914.
[14] MÒDOL T, BRICE N, RUIZ DE GALARRETA M, et al. Fibronectin peptides as potential regulators of hepatic fibrosis through apoptosis of hepatic stellate cells[J]. J Cell Physiol, 2015, 230(3):546-553.
[15] KOU X Y, SUN Y Y, LI S J, et al. Pharmacology study of the multiple angiogenesis inhibitor RC28-E on anti-fibrosis in a chemically induced lung injury model[J]. Biomolecules, 2019, 9(11):644.
[16] WANG C, LI Y L, LI H, et al. Disruption of FGF signaling ameliorates inflammatory response in hepatic stellate cells[J]. Front Cell Dev Biol,2020, 8:601.
[17] TAO L, MA W T, WU L, et al. Glial cell line-derived neurotrophic factor(GDNF)mediates hepatic stellate cell activation via ALK5/Smad signalling[J]. Gut, 2019, 68(12):2214-2227.
[18] ZHANG Q H, XIANG S H, LIU Q Q, et al. PPAR γ antagonizes hypoxia-induced activation of hepatic stellate cell through cross mediating PI3K/AKT and cGMP/PKG signaling[J]. PPAR Res, 2018,2018:6970407.
[19] STEFANOVIC B, MANOJLOVIC Z, VIED C, et al. Discovery and evaluation of inhibitor of LARP6 as specific antifibrotic compound[J].Sci Rep, 2019, 9(1):326.
[20] ZUO S K, WANG B, LIU J, et al. ER-anchored CRTH2 antagonizes collagen biosynthesis and organ fibrosis via binding LARP6[J]. EMBO J,2021, 40(16):e107403.
[21] FAN W G, LIU T H, CHEN W, et al. ECM1 prevents activation of transforming growth factor β, hepatic stellate cells, and fibrogenesis in mice[J]. Gastroenterology, 2019, 157(5):1352-1367.
[22] SUN W Y, GU Y J, LI X R, et al.Β-arrestin2 deficiency protects against hepatic fibrosis in mice and prevents synthesis of extracellular matrix[J]. Cell Death Dis, 2020, 11(5):389.
[23] IIMURO Y, NISHIO T, MORIMOTO T, et al. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat[J].Gastroenterology, 2003, 124(2):445-458.
[24] GARCIA-BAÑUELOS J, SILLER-LOPEZ F, MIRANDA A, et al.Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion[J].Gene Ther, 2002, 9(2):127-134.
[25] RODERFELD M, WEISKIRCHEN R, WAGNER S, et al. Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice[J].FASEB J, 2006, 20(3):444-454.
[26] TSAY H C, YUAN Q G, BALAKRISHNAN A, et al. Hepatocytespecific suppression of microRNA-221-3p mitigates liver fibrosis[J]. J Hepatol, 2019, 70(4):722-734.
[27] KLEPFISH M, GROSS T, VUGMAN M, et al. LOXL2 inhibition paves the way for macrophage-mediated collagen degradation in liver fibrosis[J]. Front Immunol, 2020, 11:480.
[28] CHEN G B, XIA B, FU Q, et al. Matrix mechanics as regulatory factors and therapeutic targets in hepatic fibrosis[J]. Int J Biol Sci, 2019, 15(12):2509-2521.
[29] MOSSANEN J C, KRENKEL O, CAN E G, et al. Chemokine(C-C motif)receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury[J]. Hepatology, 2016, 64(5):1667-1682.
[30] FRIEDMAN S L, RATZIU V, HARRISON S A, et al. A randomized,placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis[J]. Hepatology, 2018, 67(5):1754-1767.
[31] YOUNOSSI Z M, STEPANOVA M, LAWITZ E, et al. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib[J]. Liver Int, 2018, 38(10):1849-1859.
[32] RATZIU V, SANYAL A, HARRISON S A, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis:final analysis of the phase 2b CENTAUR study[J]. Hepatology, 2020, 72(3):892-905.
[33] BOULTER L, GOVAERE O, BIRD T G, et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease[J]. Nat Med, 2012, 18(4):572-579.
[34] DUFFIELD J S, FORBES S J, CONSTANDINOU C M, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair[J]. J Clin Invest, 2005, 115(1):56-65.
[35] CHANG J, HISAMATSU T, SHIMAMURA K, et al. Activated hepatic stellate cells mediate the differentiation of macrophages[J]. Hepatol Res,2013, 43(6):658-669.
[36] MATSUDA M, SEKI E. The liver fibrosis niche:novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells,endothelial cells, and extracellular matrix[J]. Food Chem Toxicol, 2020,143:111556.
[37] THAPA M, CHINNADURAI R, VELAZQUEZ V M, et al. Liver fibrosis occurs through dysregulation of MyD88-dependent innate B-cell activity[J]. Hepatology, 2015, 61(6):2067-2079.
[38] WYNN T A. Fibrotic disease and the T(H)1/T(H)2paradigm[J]. Nat Rev Immunol, 2004, 4(8):583-594.
[39] ZHANG M J, ZHANG S. T cells in fibrosis and fibrotic diseases[J].Front Immunol, 2020, 11:1142.
[40] LIU Y, LU T F, ZHANG C, et al. Activation of YAP attenuates hepatic damage and fibrosis in liver ischemia-reperfusion injury[J]. J Hepatol,2019, 71(4):719-730.
[41] MOORING M, FOWL B H, LUM S Z C, et al. Hepatocyte stress increases expression of yes-associated protein and transcriptional coactivator with PDZ-binding motif in hepatocytes to promote parenchymal inflammation and fibrosis[J]. Hepatology, 2020, 71(5):1813-1830.
[42] RONG X L, YANG Y Y, ZHANG G K, et al. Antler stem cells as a novel stem cell source for reducing liver fibrosis[J]. Cell Tissue Res,2020, 379(1):195-206.
[43] LAN L, LIU R, QIN L Y, et al. Transplantation of bone marrow-derived endothelial progenitor cells and hepatocyte stem cells from liver fibrosis rats ameliorates liver fibrosis[J]. World J Gastroenterol, 2018, 24(2):237-247.
[44] WAN J H, WEISS E, BEN MKADDEM S, et al. LC3-associated phagocytosis protects against inflammation and liver fibrosis via immunoreceptor inhibitory signaling[J]. Sci Transl Med, 2020, 12(539):eaaw8523.
[45] HERNÁNDEZ-GEA V, HILSCHER M, ROZENFELD R, et al.Endoplasmic Reticulum stress induces fibrogenic activity in hepatic stellate cells through autophagy[J]. J Hepatol, 2013, 59(1):98-104. |
